Travere Therapeutics Names Inrig Incoming Research Chief, Succeeding Rote

Dow Jones05:13

By Grace Yoon

Travere Therapeutics said Chief Research Officer William Rote plans to retire from the company in February.

Chief Medical Officer Julia Inrig will expand her responsibilities to include the company's research organization and be named executive vice president, head of research and development and along with her medical chief role, Travere said.

"Since joining Travere in 2017, Bill has played a pivotal role in transforming our company into a recognized leader in rare disease," Chief Executive Eric Dube said.

Inrig joined the biopharmaceutical company in 2022 as CMO, overseeing clinical development and operations. She previously served as the global head of the Renal Center of Excellence at Iqvia, leading the design of programs that supported regulatory approvals in kidney disease, the company said.

Write to Grace Yoon at grace.yoon@wsj.com.

- -

(END) Dow Jones Newswires

June 16, 2026 17:13 ET (21:13 GMT)

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2644798730?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-17 05:13","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2644798730","market":"us","top_or_hot":-1,"title":"Travere Therapeutics Names Inrig Incoming Research Chief, Succeeding Rote","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  By Grace Yoon \n</p>\n<p>\n  Travere <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> said Chief Research Officer William Rote plans to retire from the company in February. \n</p>\n<p>\n  Chief Medical Officer Julia Inrig will expand her responsibilities to include the company's research organization and be named executive vice president, head of research and development and along with her medical chief role, Travere said. \n</p>\n<p>\n  \"Since joining Travere in 2017, Bill has played a pivotal role in transforming our company into a recognized leader in rare disease,\" Chief Executive Eric Dube said. \n</p>\n<p>\n  Inrig joined the biopharmaceutical company in 2022 as CMO, overseeing clinical development and operations. She previously served as the global head of the Renal Center of Excellence at Iqvia, leading the design of programs that supported regulatory approvals in kidney disease, the company said. \n</p>\n<p>\n  Write to Grace Yoon at grace.yoon@wsj.com. \n</p>\n<pre style=\"white-space: pre\">\n- - \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  June 16, 2026 17:13 ET (21:13 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Travere Therapeutics Names Inrig Incoming Research Chief, Succeeding Rote</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTravere Therapeutics Names Inrig Incoming Research Chief, Succeeding Rote\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2026-06-17 05:13</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  By Grace Yoon \n</p>\n<p>\n  Travere <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> said Chief Research Officer William Rote plans to retire from the company in February. \n</p>\n<p>\n  Chief Medical Officer Julia Inrig will expand her responsibilities to include the company's research organization and be named executive vice president, head of research and development and along with her medical chief role, Travere said. \n</p>\n<p>\n  \"Since joining Travere in 2017, Bill has played a pivotal role in transforming our company into a recognized leader in rare disease,\" Chief Executive Eric Dube said. \n</p>\n<p>\n  Inrig joined the biopharmaceutical company in 2022 as CMO, overseeing clinical development and operations. She previously served as the global head of the Renal Center of Excellence at Iqvia, leading the design of programs that supported regulatory approvals in kidney disease, the company said. \n</p>\n<p>\n  Write to Grace Yoon at grace.yoon@wsj.com. \n</p>\n<pre style=\"white-space: pre\">\n- - \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  June 16, 2026 17:13 ET (21:13 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4007","symbol_name":"制药","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2644798730","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2644798730","pubTimestamp":1781644380,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Travere Therapeutics said Chief Research Officer William Rote plans to retire from the company in February.Chief Medical Officer Julia Inrig will expand her responsibilities to include the company's research organization and be named executive vice president, head of research and development and along with her medical chief role, Travere said.\"Since joining Travere in 2017, Bill has played a pivotal role in transforming our company into a recognized leader in rare disease,\" Chief Executive Eric Dube said.Inrig joined the biopharmaceutical company in 2022 as CMO, overseeing clinical development and operations. She previously served as the global head of the Renal Center of Excellence at Iqvia, leading the design of programs that supported regulatory approvals in kidney disease, the company said.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4007":"制药","FFTY":"Innovator IBD 50 ETF","TVTX":"Travere Therapeutics, Inc.","BK4539":"次新股","LENZ":"Therapeutics","BK4139":"生物科技"},"translate_title":"Travere Therapeutics任命Inrig为新任研究主管，接替Rote","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"FFTY":1.5,"LENZ":1.5,"TVTX":0.9},"content_text":"By Grace Yoon \n\n\n  Travere Therapeutics said Chief Research Officer William Rote plans to retire from the company in February. \n\n\n  Chief Medical Officer Julia Inrig will expand her responsibilities to include the company's research organization and be named executive vice president, head of research and development and along with her medical chief role, Travere said. \n\n\n  \"Since joining Travere in 2017, Bill has played a pivotal role in transforming our company into a recognized leader in rare disease,\" Chief Executive Eric Dube said. \n\n\n  Inrig joined the biopharmaceutical company in 2022 as CMO, overseeing clinical development and operations. She previously served as the global head of the Renal Center of Excellence at Iqvia, leading the design of programs that supported regulatory approvals in kidney disease, the company said. \n\n\n  Write to Grace Yoon at grace.yoon@wsj.com. \n\n\n- - \n\n\n  (END) Dow Jones Newswires\n\n\n  June 16, 2026 17:13 ET (21:13 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"executive","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.44.0","shortVersion":"4.44.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2644798730","isCrawlerRequest":true}